Red Star Capital Bureau reported on May 22 that on May 20, Jiangsu Public Resources Trading Center issued a notice on adjusting the supply price of some vaccines. Among them, the bid winning price of four valent influenza virus split vaccine of Changchun Institute, Wuhan Institute and Shanghai Institute under Sinopharm Group fell from 128 yuan/piece to 88 yuan/piece, a decrease of more than 30%.
According to the batch issuance information of biological products of the China Institute for Food and Drug Control, the main suppliers of tetravalent influenza vaccine in China at present include Hualan Vaccine, Jindik, Wuhan Institute of Biology, Changchun Institute of Biology, etc.
It is worth noting that the product of this price reduction is "the first new dose of tetravalent influenza virus split vaccine for infants and young children in China". The coverage advantage of all age groups superimposes the price advantage, which may cause pressure on peers such as Hualan Vaccine, Sinovac and Jindik. Among them, Hualan Vaccine, the "leader of influenza vaccine" with a single source of income, bears the brunt. According to the financial report, the main product sold by Hualan Vaccine is influenza vaccine, and the number of tetravalent influenza vaccine batches issued accounts for 85.44% of the total number of batches issued by the company.
After the price of immunization program is reduced to 60 yuan, the self paid price will be reduced by another 30%
According to the vaccine antigen composition, influenza virus split vaccine can be divided into trivalent vaccine and tetravalent vaccine. The trivalent vaccine can prevent three types of influenza A (H1N1), H3N2 and B (V), and the tetravalent vaccine can additionally prevent the B (Y) type of influenza, with higher market acceptance, and the price is generally twice that of the trivalent vaccine.
Taking the 2023 Beijing Center for Disease Control and Prevention non immunization planning influenza vaccine procurement project as an example, the price of a single trivalent influenza virus split vaccine for people over 36 months of age is 53-65 yuan, and the price of a single tetravalent influenza virus split vaccine is 128 yuan; The price of a single trivalent influenza virus split vaccine for people aged 6 to 35 months is 31 yuan to 68 yuan, and the price of a single trivalent influenza virus split vaccine is 128 yuan to 166 yuan.
In order to obtain higher profits, more and more vaccine companies have begun to deploy tetravalent influenza vaccines. In 2023, Hualan Biological's trivalent vaccine lot will be wholesale 6 times, while the tetravalent vaccine lot will be wholesale 88 times, which is the main product. From 2018 to 2023, tetravalent vaccines of Hualan Biology, Jindik, Changchun Biology, Kexing Biology and other enterprises were successively approved for listing. As the number of enterprises increased, the focus of competition began to shift to children's dosage forms, and further "rolled" to the price.
According to the requirements of the Implementation Plan for Centralized Procurement of Vaccines under the Non Immunization Program of Jiangsu Province (Trial) and the enterprise application, the price of the pre filled tetravalent influenza vaccine from Changchun Institute, Wuhan Institute and Shanghai Institute was reduced from 128 yuan/piece to 88 yuan/piece, and Sinopharm Group launched the first shot of reducing the price of influenza vaccine by up to 30%.
But this is not the first time the price of influenza vaccine has been reduced. At present, influenza vaccines belong to non immunization planning vaccines, and residents need to voluntarily pay for vaccination. However, in Beijing and other areas where influenza vaccines are included in the management of immunization planning, the price of influenza vaccines has declined. Taking the 2023 Beijing Center for Disease Control and Prevention immunization planning influenza vaccine procurement project as an example, the single trivalent influenza vaccine costs 23 yuan, The price of a single tetravalent influenza vaccine is 60 yuan.
In addition, in August 2021, the Center for Disease Control and Prevention of Shandong Province released the "Shandong Province 2021-2022 influenza vaccine centralized volume bargaining procurement document". Although according to the results of the selection, the price range of tetravalent influenza virus split vaccine is still high (118 yuan/piece – 138 yuan/piece), the purchase method of "price with quantity" has caused extensive discussion in the industry.
Domestic bivalent HPV vaccines also hit a new low price, Reduce to less than 100 yuan
Previously, the price floor of domestic bivalent HPV (human papillomavirus) vaccine was also refreshed again.
At the end of April, Hainan Provincial Center for Disease Control and Prevention's 2024 Hainan Provincial Girls' HPV Vaccine Procurement Project showed that Watson Biological Bivalent HPV Vaccine won the bid at a price of 63 yuan per piece, with a bid winning amount of 6.741 million yuan, far less than the budget of 13.91 million yuan.
Just a month ago, the bivalent HPV vaccine just dropped below 100 yuan. The announcement on the purchase of bivalent HPV vaccine released by the Jiangsu Government Procurement Network shows that the bid winning price of Wantai Biology is 86 yuan per piece.
Public data show that HPV is a DNA virus, which can be divided into high-risk (carcinogenic) and low-risk (non carcinogenic) types according to different carcinogenicity. HPV vaccine can prevent most cervical cancer, and bivalent HPV vaccine is mainly aimed at HPV16 and HPV18 infection.
In 2020, Vantai Biological bivalent HPV vaccine Xinkening will be officially marketed in China (excluding Hong Kong, Macao and Taiwan), becoming the first cervical cancer prevention product in China and the fourth in the world.
At that time, the tetravalent HPV vaccine Jiadatuo 4 and the nine valent HPV vaccine Jiadatuo 9 of the multinational pharmaceutical company MSD were listed in China in 2017 and 2018 respectively, and even earlier, GlaxoSmithKline's bivalent HPV vaccine Cervarix was listed in China in 2016.
On the premise that there is no significant advantage in the time to market and the scope of prevention, Wantai Biology has embarked on the road of "economical and applicable".
According to the Guangdong Expert Consensus on the Application of HPV Vaccine to Eliminate Cervical Cancer issued by the Cervical Cancer Prevention Professional Committee of Guangdong Preventive Medicine Association in November 2021, the bid winning prices of Jiadaxiu 4, Jiadaxiu 9 and Cervarix in Guangdong Province (2021) are 810 yuan, 1310 yuan and 590 yuan respectively.
At that time, the bid winning price of Vantai Biology was nearly half cheaper than GlaxoSmithKline, and far lower than that of the Jiadaxiu series, which was 339 yuan per piece. Calculated by three doses of inoculation, Xinkening can save 700 yuan than Cervarix.
In addition, the listing of MSD's Jiadaxiu 9 in China was an emergency approval. It took only 8 days from the application to the approval of listing, and it was faced with a large capacity shortage. "One stitch is hard to find" has been staged many times, which also provided an entry opportunity for Wantai Biology.
Due to the low price and insufficient capacity of competitors, Wantai Biological bivalent HPV vaccine became popular on the market, becoming the company's "performance accelerator". In May 2020, when it was put into the market, Wantai Biological realized 2 million bivalent HPV vaccines, with an operating income of 693 million yuan.
In 2021, the first full year after the launch of Wantai biological bivalent HPV vaccine, the operating income of vaccine products will reach 3.278 billion yuan, up 360.75% year on year. In 2022, the sales volume of bivalent HPV vaccine of Wantai Biology will exceed 25 million.
Editor Xiao Ziqi synthesizes daily economic news and surging news
